JP Morgan Chase
XLO icon

JP Morgan Chase’s Xilio Therapeutics XLO Stock Holding History

JP Morgan Chase’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-240
Closed -$1.98K – 8129
2026
Q1 		$1.98K Buy
+240
New +$1.97K ﹤0.01% 7017
2025
Q2 		– Sell
-4
Closed -$45 – 7715
2025
Q1 		$45 Sell
4
-1
-20% -$13 ﹤0.01% 7000
2024
Q4 		$63 Hold
5
– – ﹤0.01% 7088
2024
Q3 		$59 Buy
5
+1
+25% +$12 ﹤0.01% 7087
2024
Q2 		$56 Sell
4
-192
-98% -$3.01K ﹤0.01% 7010
2024
Q1 		$2.96K Sell
196
-8
-4% -$77 ﹤0.01% 6529
2023
Q4 		$1.57K Buy
204
+10
+5% +$198 ﹤0.01% 6759
2023
Q3 		$5.74K Buy
194
+1
+0.5% +$37 ﹤0.01% 6356
2023
Q2 		$7.08K Hold
193
– – ﹤0.01% 6108
2023
Q1 		$9K Hold
193
– – ﹤0.01% 6144
2022
Q4 		$7K Hold
193
– – ﹤0.01% 6106
2022
Q3 		$8K Sell
193
-2
-1% -$78 ﹤0.01% 6011
2022
Q2 		$8K Sell
195
-151
-44% -$7.99K ﹤0.01% 6083
2022
Q1 		$34K Sell
346
-489
-59% -$77.4K ﹤0.01% 5928
2021
Q4 		$187K Buy
+835
New +$199K ﹤0.01% 5401

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase's XLO Position: Q2 2026 in Review

JP Morgan Chase sold out of Xilio Therapeutics (XLO) in Q2 2026, closing a stake of 240 shares — an estimated $1.98K sold.

JP Morgan Chase first reported a position in XLO in Q4 2021 and held it in 15 quarters. The position peaked at $187K in Q4 2021. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • JP Morgan Chase reported no remaining Xilio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • JP Morgan Chase sold 240 Xilio Therapeutics shares in Q2 2026, an estimated $1.98K.
  • JP Morgan Chase first reported a position in Xilio Therapeutics in Q4 2021 and held it in 15 quarters.
  • JP Morgan Chase's Xilio Therapeutics position peaked at $187K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.